Drug intelligence / Profile preview

CHC shRNA

Development stage
Preclinical
Lead developer
Academia Sinica
Modality
Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
Administration
Intratumoral
01

Overview

CHC shRNA is a short hairpin RNA (shRNA) therapeutic candidate designed to silence the expression of clathrin heavy chain (CHC). Research conducted at Academia Sinica has identified CHC as a critical regulator of tumor growth and angiogenesis, beyond its traditional role in endocytosis. The mechanism involves CHC binding to and stabilizing the transcription factor subunit HIF-1α, facilitating its nuclear translocation and subsequent upregulation of VEGF expression. By knocking down CHC, this shRNA disrupts the HIF-1α/VEGF signaling axis, leading to inhibited tumor cell proliferation, colony formation, and vessel formation. Preclinical studies in NOD/SCID mice bearing pancreatic cancer xenografts have demonstrated that CHC shRNA can effectively inhibit tumor progression and angiogenesis.

Other names
clathrin heavy chain shRNAshRNA-CHCCLTC shRNA
02

Targets

HC (Haptocorrin)

Beyond the preview

Go deeper on CHC shRNA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on CHC shRNA.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call